Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 15/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620161 | 1.00 | PTPN1 (0.48) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL6908883 | 0.95 | PTPN1 (0.45) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL14601934 | 0.90 | LGALS8 (0.47) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL6907757 | 0.90 | LGALS8 (0.47) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL9299084 | 0.90 | PTPN1 (0.42) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL16897723 | 0.89 | LGALS3 (0.53) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL7147800 | 0.88 | LGALS3 (0.47) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL7147794 | 0.88 | LGALS3 (0.47) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL7149488 | 0.88 | LGALS3 (0.47) | PTPN1LGALS3LGALS4LGALS9LGALS1 | |
| SCHEMBL7149484 | 0.88 | LGALS3 (0.47) | PTPN1LGALS3LGALS4LGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247621-B2 | Antiviral phosphonate compounds and methods therefor | VALEANT RESEARCH & DEVELOPMENT (US) | 2007-07-24 | — | — | US | disclosed |
| US-20040023921-A1 | Antiviral phosphonate compounds and methods therefor | VRX HOLDCO LLC | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023921-A1 | Antiviral phosphonate compounds and methods therefor | POLRMT, CPSF7, RNGTT | PTPN1 2288/4885LGALS3 4114/4885LGALS4 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.